CHPG is a selective mGluR5 agonist used to attenuate SO₂-induced oxidative stress and inflammation in BV2 microglial cells via the TSG-6/NF-κB pathway; it prevents traumatic brain injury (TBI) both in vitro and in vivo through the ERK and Akt signaling pathways; it increases cell viability, reduces LDH release, protects against SO₂-induced apoptosis, upregulates TSG-6 expression at both mRNA and protein levels in BV2 cells, and significantly reduces cerebral lesion volume in a rat model of TBI following intracerebral injection.